Results of the Compare-Acute trial show that STEMI patients benefit from complete revascularization guided by fractional flow reserve measurement, but most of this benefit was driven by the reduction in repeat revascularization. Investigators say more research will be needed to determine if this approach can reduce mortality or other "hard" endpoints.
Results from the Compare-Acute trial show that using fractional flow reserve measurements to guide complete revascularization of all the coronary arteries while treating a lesion causing an ST-segment elevation myocardial infarction (STEMI) can reduce patients' risk of needing another revascularization.
Primary investigator Pieter Smits, Maasstad Hospital in Rotterdam, presented the one-year Compare-Acute results at the American College of Cardiology meeting...
The ceramic device, designed to reduce complications, will be exclusively distributed by Zimmer Biomet and initially available in 30 hospitals, with broader European access expected by 2026.
A Japanese study of Watchman LAA closure devices found that leaks of any size after implantation raise the risk of stroke. The study comes shortly after the US FDA issued an early alert for the Watchman access systems.
A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.
After receiving FDA clearance for its Genio sleep apnea implant, Nyxoah plans a major US rollout despite a patent suit from rival Inspire Medical. Genio offers bilateral nerve stimulation as a CPAP alternative, with strong trial results.
After receiving FDA clearance for its Genio sleep apnea implant, Nyxoah plans a major US rollout despite a patent suit from rival Inspire Medical. Genio offers bilateral nerve stimulation as a CPAP alternative, with strong trial results.
Synchron is preparing a pilot study of its fully wireless, second-gen brain-computer interface after an ALS patient controlled an iPad solely by thought. If all goes as planned, Synchron’s BCI will move into pivotal trials in 2026.
Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.
